Biography

1. Research Areas

Research focus: Tumor cell biology, Antibody drugs, Clinic infection

Keywords: Liver cancer, Ovarian cancer, Membrane trafficking, Endocytosis, GTPase, Multidrug-resistance, Hypoxia, Drug delivery, Nanoparticles, Antibody, Antibiotics, Infection

2. Education

2001 - 2004: PhD, (Cell Biology), Fourth Military Medical University, China

1996 - 1998: M.A. (Genetics), Jinlin University, China

1991 - 1995: B.S. (Genetics), Northwest A&F University, China

3. Professional Experience

2020-present, Professor, Nankai University, China

2012-2019, Associate Professor, Nankai University, China

2006-2009: Postdoctoral Scientist, Lund University Hospital, Sweden

2005-2011: Associate Professor, Fourth Military Medical University, China

2000-2005: Lecturer, Fourth Military Medical University, China

1998-2000: Teaching Assistant, Fourth Military Medical University, China

4. Awards

2010: Gold Award for Chinese Outstanding Patented Invention, WIPO-SIPO

2005: National Prize for Progress in Science & Technology, China

5. Social Service

2019-present, Board Member, Chinese Pharmaceutical Association

2018-present, Consultant, KingMed Diagnostics Group Co., Ltd. China

2013-present, Board Member, Chinese Anti-Cancer Association

2012-present, Board Member, China Medicinal Biotech Association

2010-present, Board Member, Chinese Society for Cell Biology

Research & Achievements

Peer-Reviewed Journal Papers

1. Sun Z, Huang JH, Su LJ, Li J, Qi FZ, Su HS, Chen YN, Zhang Q, Zhang QZ, Li ZJ, Zhang SH*. Arf6-mediated macropinocytosis-enhanced suicide gene therapy of C16TAB-condensed Tat/pDNA nanoparticles in ovarian cancer. Nanoscale, 2021, 13(34):14538-14551.

2. Zhang Q, Gao HY, Li D, Bai CS, Li Z, Zheng S, Zhang WF, Zhou YL, Zhang SH*. A TTP-incorporated scoring model for predicting mortality of solid tumor patients with bloodstream infection caused by Escherichia coli. Support Care Cancer.2021, DOI: 10.1007/s00520-021-06442-z.

3. Qi S^#, Su L^#, Li J^#, Zhang C, Ma Z, Liu G, Zhang Q, Jia G, Piao Y, Zhang S*.Arf6-driven endocytic recycling of CD147 determines HCC malignant phenotypes. J Exp Clin Cancer Res. 2019, 38(1):471.

4. Qi S, Su L, Li J, Zhao P, Zhang Q, Niu X, Liu J, Jia G, Wei X, Tavernier J, Jiang J, Chen Z, Zhang S*.YIPF2 is a novel Rab-GDF that enhances HCC malignant phenotypes by facilitating CD147 endocytic recycle. Cell Death Dis. 2019, 10(6):462.

5. Zhang Q, Gao H, Li D, Li Z, Qi S, Zheng S, Bai C, Zhang S*. Clinical outcome of Escherichia coli bloodstream infection in cancer patients with/without biofilm formation: a single-center retrospective study. Infect Drug Resist. 2019,12:359-371.

6. Niu X, Su L, Qi S, Gao Z, Zhang Q, Zhang S*. GRP75 modulates oncogenic Dbl-driven endocytosis derailed via the CHIP-mediated ubiquitin degradation pathway. Cell Death Dis. 2018, 9(10):971.

7. Niu X, Gao Z, Qi S, Su L, Yang N, Luan X, Li J, Zhang Q, An Y, Zhang S*. Macropinocytosis activated by oncogenic Dbl enables specific targeted delivery of Tat/pDNA nano-complexes into ovarian cancer cells. Int J Nanomedicine. 2018,13:4895-4911.

8．Gao Z, Niu X, Zhang Q, Chen H, Gao A, Qi S, Xiang R, Belting M, Zhang S*. Mitochondria chaperone GRP75 moonlighting as a cell cycle controller to derail endocytosis provides an opportunity for nanomicrosphere intracellular delivery. Oncotarget. 2017, 8(35):58536-58552.

9．Zhang Q, Zhang W, Li Z, Bai C, Li D, Zheng S, Zhang P, Zhang S*. Bacteraemia due to AmpC β-lactamase-producing Escherichia coli in hospitalized cancer patients: risk factors, antibiotic therapy, and outcomes. Diagn Microbiol Infect Dis. 2017, 88(3):247-251.

10．Liu J^#, Zhang Q^#, Chen H, Gao Z, Li Y, Sun Z, Xiang R, Zhang S*. Phage display library selection of a hypoxia-binding scFv antibody for liver cancer metabolic marker discovery. Oncotarget. 2016, 7(25):38105-38121.

11. Chen H, Gao Z, He C, Xiang R, van Kuppevelt TH, Belting M, Zhang S*. GRP75 upregulates clathrin-independent endocytosis through actin cytoskeleton reorganization mediated by the concurrent activation of Cdc42 and RhoA. Exp Cell Res. 2016, 343(2):223-36.

12．Zhang Q, Li D, Bai C, Zhang W, Zheng S, Zhang P, Zhang S*. Clinical prognostic factors for time to positivity in cancer patients with bloodstream infections. Infection. 2016, 44(5):583–588.

13．Zhao P, Zhang W, Wang SJ, Yu XL, Tang J, Huang W, Li Y, Cui HY, Guo YS, Tavernier J, Zhang SH*, Jiang JL*, Chen ZN*. HAb18G/CD147 promotes cell motility by regulating annexin II-activated RhoA and Rac1 signaling pathways in HCC cells. Hepatology. 2011,54(6):2012-24.

14. Zhao P, Zhang W, Tang J, Ma XK, Li Y, Jiang JL*, Zhang SH*,Chen ZN*. Annexin II promotes invasion and migration of human hepatocellular carcinoma cells in vitro via its interaction with HAb18G/CD147. Cancer Sci.2010,101(2):387–395.

15. Zhang Q^#, Zhang SH^#, Su MQ, Bao GQ, Liu JY, Yi J, Shen JJ, Hao XK*. Guided selection of an anti-gamma-seminoprotein human Fab for antibody directed enzyme prodrug therapy of prostate cancer. Cancer Immunol Immunother.2007,56(4):477-89.

16. Zhang SH, Xing JL, Zhang Q, Song F, Li Y, Yang XM, Chen ZN*. Optimal design of Ig 5’primers for construction of diverse phage antibody library established to select anti-HAb18GEF and anti-DOTA-Y Fabs for hepatoma pretargeting RIT. Front Biosci, 2006,11,1733 -1749.

21. Wittrup A, Zhang SH, Belting M*，Studies of Proteoglycan Involvement in CPP-Mediated Delivery. Cell-Penetrating Peptides. Methods Mol Biol. 2011;683:99-115.

22. Kong LM, Liao CG, Chen L, Yang HS, Zhang SH, Zhang Z, Bian HJ, Xing JL, ChenZN*. Promoter hypomethylation up-regulates CD147 expression through increasing Sp1 binding and associates with poor prognosis in human hepatocellular carcinoma.J Cell Mol Med. 2011,15(6):1415-28.

23. Wittrup A, Zhang SH, P. Kucharzewska, Johansson M, Welch J, Mörgelin M, Belting M*. Magnetic nanoparticle based isolation of endocytic vesicles reveals a functional role of the heat shock protein GRP75 in macromolecular delivery. Proc Natl Acad Sci U S A. 2010，107(30):13342-7.

24. Wittrup A, Zhang SH, ten Dam GB, van Kuppevelt TH, Bengtson P, Johansson M, Welch J, Mörgelin M, Belting M*. ScFv antibody-induced translocation of cell-surface heparan sulfate proteoglycan to endocytic vesicles: evidence for heparan sulfate epitope specificity and role of both syndecan and glypican. J Biol Chem. 2009,284(47):32959-67.

25. Xu J, Shen ZY, Chen XG, Zhang Q, Bian HJ, Zhu P, Xu HY, Song F, Yang XM, Mi L, Zhao QC, Tian R, Feng Q, Zhang SH, Li Y, Jiang JL, Li L, Yu XL, Zhang Z, Chen ZN*. A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation. Hepatology. 2007,45(2):269-76.

26. ZN Chen, L Mi, J Xu, F Song, Q Zhang, Z Zhang, JL Xing, HJ Bian, JL Jiang, P Shang, AR Qian, SH Zhang, L Li, Y Li, P Zhu*. Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: clinical phase I/II trials. Int J Radiat Oncol Biol Phys. 2006，65(2):435-44.

27. Wang L, Ku XM, Li Y, Bian HJ, Zhang SH, Chen ZN*.  Regulation of matrix metalloproteinase production and tumor cell invasion by four monoclonal antibodies against different epitopes of HAb18G/CD147 extracellular domain. Hybridoma. 2006, 25(2):60-7.

Projects

National Science and Technology Major Project of China (2011ZX09506, 2009ZX09301)

National Natural Science Fund of China (81373318, 30400246)

National Translational Science Center for Molecular Medicine Fund (F1034361)

The Ministry of Education Fund of China (20130031120037, 033781)

Chinese Pharmacertical Association-Yiling Pharmacertical Innovation Fund (CPAYLJ202003)

Key Research Fund of Tianjin Project & Team (XB202010)

Key Research and Development Program of Tianjin (20YFZCSY00450)

Natural Science Fund of Tianjin (13JCYBJC21000, 6JCYBJC23900)

Nankai University & Cangzhou Bohai New Area Scientific Research Cultivation Fund (NCC2020PY20)

Teaching

Undergraduates: Medical Cell Biology

Graduates: Progresses of Antibody & Vaccine Research, Introduction to Human Diseases